Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 20/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 20/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4590713 | 0.88 | CYP3A4 (0.74) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL4982224 | 0.83 | CYP3A4 (0.78) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL4591365 | 0.80 | CYP3A4 (0.73) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL4590766 | 0.80 | CYP3A4 (0.70) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL20987029 | 0.77 | CYP3A4 (0.56) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL6351763 | 0.77 | CYP3A4 (0.67) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL4591169 | 0.77 | CYP3A4 (0.70) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL4591130 | 0.77 | CYP3A4 (0.68) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL4987563 | 0.76 | CYP3A4 (0.79) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL5257211 | 0.76 | CYP3A4 (0.64) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040067252-A1 | Novel modified release formulation | ASTRAZENECA AB (SE) | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067252-A1 | Novel modified release formulation | ABCB11, SLC47A1, LIPA | CYP3A4 689/4885CYP2C9 1291/4885CYP2D6 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.